CO5540383A2 - UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI)FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERT-BUTOXI CARBONIL-AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO E INSULINA - Google Patents
UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI)FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERT-BUTOXI CARBONIL-AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO E INSULINAInfo
- Publication number
- CO5540383A2 CO5540383A2 CO03112112A CO03112112A CO5540383A2 CO 5540383 A2 CO5540383 A2 CO 5540383A2 CO 03112112 A CO03112112 A CO 03112112A CO 03112112 A CO03112112 A CO 03112112A CO 5540383 A2 CO5540383 A2 CO 5540383A2
- Authority
- CO
- Colombia
- Prior art keywords
- etoxi
- phenyl
- ethoxy
- propanoic
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Una combinación farmacéutica que comprende uno cualquiera de ácido (S)-2-etoxi-3-[4-(2-{4-metanosulfoniloxifenil)etoxi)fenil] propanoico o 3-{4-[2-(4-tert-butoxicarbonilaminofenil)etoxi]fenil)-(S)-2-etoxi propanoico, o una sal farmacéuticamente aceptable de los mismos y solvatos cualesquiera de uno cualquiera de los mismos e insulina.8.- Una combinación de productos que comprende:(1) una formulación farmacéutica que incluye uno cualquiera de ácido (S)-2-etoxi-3-[4-(2-{4-metano-sulfoniloxifenil}etoxi)fenil] propanoico o ácido 3-{4-[2-(4-tert-butoxicarbonil-aminofenil)-etoxi]fenil}-(S)-2-etoxi propanoico, o una sal farmacéuticamente aceptable de los mismos e insulina, en mezcla con un coadyuvante, diluyente o portador farmacéuticamente aceptables; y(2) un kit de partes que comprende componentes:(a) una formulación farmacéutica que incluye uno cualquiera de ácido (S)-2-etoxi-3-[4-(2-{4-metano-sulfoniloxifenil}etoxi)fenil] propanoico o ácido 3-{4-[2-(4-tert-butoxicarbonil-aminofenil)-etoxi]fenil}-(S)-2-etoxi propanoico, o una sal farmacéuticamente aceptable de los mismos en mezcla con un coadyuvante, diluyente o portador farmacéuticamente aceptables; y(b) una formulación farmacéutica que incluye insulina en mezcla con un coadyuvante, diluyente o portador farmacéuticamente aceptables, los cuales componentes (a) y (b) se proveen cada uno en una forma que es apropiada para administración en conjunción con el otro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101981A SE0101981D0 (sv) | 2001-06-01 | 2001-06-01 | Pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540383A2 true CO5540383A2 (es) | 2005-07-29 |
Family
ID=20284363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03112112A CO5540383A2 (es) | 2001-06-01 | 2003-12-23 | UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI)FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERT-BUTOXI CARBONIL-AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO E INSULINA |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040147600A1 (es) |
| EP (1) | EP1401485A1 (es) |
| JP (1) | JP2004532873A (es) |
| KR (1) | KR20040072027A (es) |
| CN (1) | CN1535155A (es) |
| BR (1) | BR0210129A (es) |
| CA (1) | CA2448637A1 (es) |
| CO (1) | CO5540383A2 (es) |
| CZ (1) | CZ20033233A3 (es) |
| EE (1) | EE200300577A (es) |
| HU (1) | HUP0400964A3 (es) |
| IL (1) | IL159034A0 (es) |
| IS (1) | IS7056A (es) |
| MX (1) | MXPA03011012A (es) |
| NO (1) | NO20035236D0 (es) |
| NZ (1) | NZ529812A (es) |
| PL (1) | PL367704A1 (es) |
| RU (1) | RU2003136156A (es) |
| SE (1) | SE0101981D0 (es) |
| SK (1) | SK14712003A3 (es) |
| WO (1) | WO2002096453A1 (es) |
| ZA (1) | ZA200309261B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60308390T2 (de) * | 2003-11-28 | 2007-09-06 | Merck Santé | Behandlung von Hyperurikämie |
| AR052888A1 (es) * | 2005-01-28 | 2007-04-11 | Lilly Co Eli | Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion |
| CN102036559A (zh) * | 2008-05-19 | 2011-04-27 | 雀巢产品技术援助有限公司 | 降低动物脂质吸收的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| SE9801990D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| EP1145717B1 (en) * | 2000-04-13 | 2004-05-12 | Pfizer Products Inc. | Synergistic effect of glyburide and milrinone |
-
2001
- 2001-06-01 SE SE0101981A patent/SE0101981D0/xx unknown
-
2002
- 2002-05-30 KR KR10-2003-7015636A patent/KR20040072027A/ko not_active Application Discontinuation
- 2002-05-30 EE EEP200300577A patent/EE200300577A/xx unknown
- 2002-05-30 RU RU2003136156/15A patent/RU2003136156A/ru not_active Application Discontinuation
- 2002-05-30 PL PL02367704A patent/PL367704A1/xx not_active Application Discontinuation
- 2002-05-30 IL IL15903402A patent/IL159034A0/xx unknown
- 2002-05-30 CN CNA028149645A patent/CN1535155A/zh active Pending
- 2002-05-30 JP JP2002592962A patent/JP2004532873A/ja not_active Withdrawn
- 2002-05-30 MX MXPA03011012A patent/MXPA03011012A/es unknown
- 2002-05-30 NZ NZ529812A patent/NZ529812A/xx unknown
- 2002-05-30 US US10/479,707 patent/US20040147600A1/en not_active Abandoned
- 2002-05-30 SK SK1471-2003A patent/SK14712003A3/sk not_active Application Discontinuation
- 2002-05-30 CA CA002448637A patent/CA2448637A1/en not_active Abandoned
- 2002-05-30 HU HU0400964A patent/HUP0400964A3/hu unknown
- 2002-05-30 CZ CZ20033233A patent/CZ20033233A3/cs unknown
- 2002-05-30 WO PCT/SE2002/001037 patent/WO2002096453A1/en not_active Application Discontinuation
- 2002-05-30 EP EP02736371A patent/EP1401485A1/en not_active Withdrawn
- 2002-05-30 BR BR0210129-7A patent/BR0210129A/pt not_active IP Right Cessation
-
2003
- 2003-11-25 NO NO20035236A patent/NO20035236D0/no not_active Application Discontinuation
- 2003-11-27 ZA ZA200309261A patent/ZA200309261B/en unknown
- 2003-11-28 IS IS7056A patent/IS7056A/is unknown
- 2003-12-23 CO CO03112112A patent/CO5540383A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ529812A (en) | 2006-03-31 |
| IL159034A0 (en) | 2004-05-12 |
| HUP0400964A2 (hu) | 2004-08-30 |
| PL367704A1 (en) | 2005-03-07 |
| EE200300577A (et) | 2004-02-16 |
| SE0101981D0 (sv) | 2001-06-01 |
| MXPA03011012A (es) | 2004-02-27 |
| EP1401485A1 (en) | 2004-03-31 |
| KR20040072027A (ko) | 2004-08-16 |
| BR0210129A (pt) | 2004-06-08 |
| NO20035236D0 (no) | 2003-11-25 |
| IS7056A (is) | 2003-11-28 |
| CZ20033233A3 (cs) | 2004-12-15 |
| HUP0400964A3 (en) | 2007-11-28 |
| US20040147600A1 (en) | 2004-07-29 |
| RU2003136156A (ru) | 2005-05-20 |
| ZA200309261B (en) | 2005-02-28 |
| CN1535155A (zh) | 2004-10-06 |
| CA2448637A1 (en) | 2002-12-05 |
| SK14712003A3 (sk) | 2004-08-03 |
| JP2004532873A (ja) | 2004-10-28 |
| WO2002096453A1 (en) | 2002-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9910913A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina | |
| AR054261A1 (es) | Sales fisiologicamente compatibles de ester etilico del acido 3-(2-{(4-(hexiloxicarbonilamino-imino-metil )-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico, composiciones farmaceuticas que las contienen y su uso en la preparacion de un medicamento para la profil | |
| PA8529501A1 (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7." | |
| CO4930276A1 (es) | Nuevos derivados de aminofosfohato y proceso de prepara cion | |
| CO5700781A2 (es) | Agonistas morfolinicos de la dopamina | |
| IS6399A (is) | Mulið form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýloxýfenýl}etoxý)fenýl]própanónsýra | |
| AR041340A1 (es) | Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen | |
| CO5540383A2 (es) | UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI)FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERT-BUTOXI CARBONIL-AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO E INSULINA | |
| CO5540382A2 (es) | UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI) FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERTBUTOXI CARBONIL AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO Y UNA SULFONILUREA | |
| CO5630026A2 (es) | Sales de amina de acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[metilsulfonil)oxi]fenoxi}etil)fenil]propanoico y su uso en medicina | |
| PE20040669A1 (es) | Derivados de fenilalanina enamida | |
| BR9810405A (pt) | Composição que compreende 5-[4-[2-(n-metil-n-2-piridil) amino) etoxi] benzil] tiazolidino-2,4-diona | |
| UY27461A1 (es) | Formas pseudopolimorficas de cardevilol. | |
| AR016501A1 (es) | Compuestos inhibidores de las fkbp, composiciones farmaceuticas, uso para la preparacion de medicamentos y procesos de preparacion e intermediarios. | |
| EE200300584A (et) | Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja biguaniidravimit | |
| AR046719A1 (es) | Sales de benzazepina y composiciones farmacéuticas que las contienen. | |
| CO4960663A1 (es) | Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol | |
| UY28367A1 (es) | Agentes terapéuticos | |
| AR040378A1 (es) | Formulaciones farmaceuticas de liberacion controlada | |
| ATE350038T1 (de) | Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi | |
| UY28155A1 (es) | Nuevo derivado ( i ) de ácido 3 -aril-2- hidroxipropiónico | |
| ECSP982731A (es) | Inhibidores de benzotiazol de la proteina tirosina cinasa | |
| CL2004000719A1 (es) | Procedimiento de preparacion de acidos pirrolidin-1,2-dicarboxilico-1-[(4-cloro-fenil)-amido]-2{[(3-oxo-morfolin-4-il)-fenil]-amida} y uno de los intermediarios que se usan en el procedimiento. | |
| UY26365A1 (es) | Sales de disodio, monohidratos, solvatos de etanol para la liberación de agentes activos | |
| ECSP003602A (es) | PRODUCTOS DE LA DROGA ß- CARBOLINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |